Our Science

Vepdegestrant Collaboration

In July 2021, Arvinas and Pfizer Inc. announced a global collaboration to develop and commercialize vepdegestrant, an investigational, oral, estrogen-receptor-targeting PROTAC® degrader. This partnership combines Arvinas’ PROTAC expertise with Pfizer’s deep experience in breast oncology therapeutics. Arvinas and Pfizer will equally share worldwide development costs, commercialization expenses, and profits.

E3 Ligase Collaboration

In December 2023, Arvinas and Pfizer Inc. entered into a research agreement to identify novel binders to E3 ligases which can potentially be leveraged in future heterobifunctional molecules. Under this collaboration, Pfizer will screen its proprietary compound library for E3 ligase binders and Arvinas will subsequently optimize identified hits arising from these screens. Both Arvinas and Pfizer will have equal access to utilize the optimized E3 ligase binders in molecules targeting proteins in each company’s interest.

Research License

In January 2018, Arvinas announced a research and collaboration license agreement with Pfizer Inc. for the discovery and development of drug candidates using Arvinas’ PROTAC® technology platform, which is designed to degrade key disease-causing proteins. The multi-year collaboration covers multiple disease targets across several therapeutic areas. Arvinas may receive up to $830 million in upfront and potential development and commercialization milestone payments in addition to tiered royalties.

In May 2024, Arvinas out-licensed ARV-766, its second generation PROTAC® androgen receptor degrader for patients with prostate cancer and sold its preclinical AR-V7 program to Novartis AG. Arvinas received a one-time, upfront payment in the aggregate amount of $150 million and is eligible to receive up to an additional $1.01 billion as contingent payments based on specified development, regulatory and commercial milestones for ARV-766 being met, as well as tiered royalties based upon worldwide net sales of ARV-766.

In November 2017, Arvinas and Genentech, a member of the Roche Group, expanded their multi-year strategic license agreement to encompass additional disease targets. The collaboration was originally formed in October 2015 to develop new therapeutics using Arvinas’ PROTAC® technology platform.

As part of the expansion, Arvinas is now eligible to receive more than $650 million in development and commercialization milestones as well as tiered royalties on sales of products. Genentech has the option to further expand the collaboration to include other disease targets for consideration.

Oerth Bio is the joint venture formed by Arvinas and Bayer in 2019 and represents an opportunity to extend the impact of PROTAC protein degraders into agriculture, including applications for weed, pest, and disease control. Oerth Bio is supported by intellectual property and over $55 million in committed funding from Bayer, and by technology and intellectual property from Arvinas. Bayer and Arvinas equally share governance and equity ownership of Oerth Bio.

In January 2023, Oerth Bio and Bayer announced a new collaboration seeking to develop the next generation of more sustainable crop protection products. The agreement recommitted Oerth Bio’s specialized expertise designing PROTAC degraders for agriculture, alongside Bayer’s global infrastructure testing, development, and commercialization experience.

For more information about Oerth Bio, please visit oerthbio.com